$VNDA
Vanda Pharmaceuticals Inc.

2022 Q4 Form 10-Q Financial Statement

#000162828022027951 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $64.48M $65.32M
YoY Change -5.2% -6.82%
Cost Of Revenue $6.238M $6.320M
YoY Change 0.03% -7.02%
Gross Profit $58.24M $59.00M
YoY Change -5.73% -6.79%
Gross Profit Margin 90.33% 90.32%
Selling, General & Admin $32.78M $29.85M
YoY Change -1.99% -8.02%
% of Gross Profit 56.28% 50.6%
Research & Development $18.45M $24.86M
YoY Change 1773.5% 26.48%
% of Gross Profit 31.68% 42.13%
Depreciation & Amortization $663.0K $678.0K
YoY Change -6.09% -4.24%
% of Gross Profit 1.14% 1.15%
Operating Expenses $51.62M $54.71M
YoY Change 54.78% 4.99%
Operating Profit $6.629M $3.908M
YoY Change -76.69% -63.88%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.984M $1.553M
YoY Change -11576.92% -1701.03%
Pretax Income $9.613M $5.461M
YoY Change 11.65% -49.07%
Income Tax $2.752M $2.200M
% Of Pretax Income 28.63% 40.29%
Net Earnings $6.861M $3.270M
YoY Change -3.07% -57.92%
Net Earnings / Revenue 10.64% 5.01%
Basic Earnings Per Share $0.06
Diluted Earnings Per Share $0.12 $0.06
COMMON SHARES
Basic Shares Outstanding 56.59M shares 56.56M shares
Diluted Shares Outstanding 56.97M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $466.9M $454.8M
YoY Change 7.87% 12.03%
Cash & Equivalents $135.0M $49.40M
Short-Term Investments $331.8M $405.4M
Other Short-Term Assets $17.73M $21.37M
YoY Change 47.77% 59.0%
Inventory $1.194M $1.590M
Prepaid Expenses
Receivables $33.51M $29.35M
Other Receivables $0.00 $0.00
Total Short-Term Assets $519.3M $507.1M
YoY Change 8.57% 9.81%
LONG-TERM ASSETS
Property, Plant & Equipment $2.573M $2.594M
YoY Change -17.35% -21.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $85.42M $84.88M
YoY Change 2.88% 0.32%
Total Long-Term Assets $115.0M $114.7M
YoY Change -0.46% -2.78%
TOTAL ASSETS
Total Short-Term Assets $519.3M $507.1M
Total Long-Term Assets $115.0M $114.7M
Total Assets $634.2M $621.8M
YoY Change 6.81% 7.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.979M $5.585M
YoY Change -15.22% -7.85%
Accrued Expenses $86.46M $87.04M
YoY Change 26.13% 32.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $91.44M $92.62M
YoY Change 22.87% 28.65%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.800M $4.605M
YoY Change 54.9% 15.36%
Total Long-Term Liabilities $6.800M $4.605M
YoY Change 54.9% 15.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $91.44M $92.62M
Total Long-Term Liabilities $6.800M $4.605M
Total Liabilities $107.0M $106.1M
YoY Change 20.46% 22.77%
SHAREHOLDERS EQUITY
Retained Earnings -$157.9M -$164.8M
YoY Change -3.82% -3.79%
Common Stock $686.3M $681.9M
YoY Change 2.54% 2.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $527.2M $515.7M
YoY Change
Total Liabilities & Shareholders Equity $634.2M $621.8M
YoY Change 6.81% 7.25%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income $6.861M $3.270M
YoY Change -3.07% -57.92%
Depreciation, Depletion And Amortization $663.0K $678.0K
YoY Change -6.09% -4.24%
Cash From Operating Activities $9.416M $12.84M
YoY Change -64.61% 36.61%
INVESTING ACTIVITIES
Capital Expenditures $263.0K -$148.0K
YoY Change -296.27% -1580.0%
Acquisitions
YoY Change
Other Investing Activities $75.69M -$21.63M
YoY Change -392.65% 30.31%
Cash From Investing Activities $75.43M -$21.78M
YoY Change -390.13% 31.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 605.0K 4.000K
YoY Change -41.88% -98.92%
NET CHANGE
Cash From Operating Activities 9.416M 12.84M
Cash From Investing Activities 75.43M -21.78M
Cash From Financing Activities 605.0K 4.000K
Net Change In Cash 85.45M -8.936M
YoY Change 5078.73% 31.03%
FREE CASH FLOW
Cash From Operating Activities $9.416M $12.84M
Capital Expenditures $263.0K -$148.0K
Free Cash Flow $9.153M $12.99M
YoY Change -65.77% 38.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001347178
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei City Area Code
CityAreaCode
202
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34186
dei Entity Registrant Name
EntityRegistrantName
VANDA PHARMACEUTICALS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
03-0491827
dei Entity Address Address Line1
EntityAddressAddressLine1
2200 Pennsylvania Avenue NW
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300E
dei Entity Address City Or Town
EntityAddressCityOrTown
Washington
dei Entity Address State Or Province
EntityAddressStateOrProvince
DC
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20037
dei Local Phone Number
LocalPhoneNumber
734-3400
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
VNDA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
29352000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32467000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
1590000 usd
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
56590048 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49397000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52071000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
405394000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
380742000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
1025000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
21373000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11996000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
507106000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
478301000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2594000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3113000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8262000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9272000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18944000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
20081000 usd
CY2022Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
74529000 usd
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
74878000 usd
CY2022Q3 vnda Inventory And Other Non Current
InventoryAndOtherNonCurrent
10353000 usd
CY2021Q4 vnda Inventory And Other Non Current
InventoryAndOtherNonCurrent
8147000 usd
CY2022Q3 us-gaap Assets
Assets
621788000 usd
CY2021Q4 us-gaap Assets
Assets
593792000 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
50125000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
34438000 usd
CY2022Q3 vnda Product Revenue Allowances Current
ProductRevenueAllowancesCurrent
42498000 usd
CY2021Q4 vnda Product Revenue Allowances Current
ProductRevenueAllowancesCurrent
39981000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
92623000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
74419000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8903000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10055000 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4605000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4390000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
106131000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
88864000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56588548 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56588548 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55900855 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55900855 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
57000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
56000 usd
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
681847000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
669223000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1485000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-175000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-164762000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-164176000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
515657000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
504928000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
621788000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
593792000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
65318000 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
70095000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
189900000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
200663000 usd
CY2022Q3 us-gaap Revenues
Revenues
65318000 usd
CY2021Q3 us-gaap Revenues
Revenues
70095000 usd
us-gaap Revenues
Revenues
189900000 usd
us-gaap Revenues
Revenues
200663000 usd
CY2022Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
6320000 usd
CY2021Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
6797000 usd
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
18044000 usd
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
19393000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24857000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19653000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
67316000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56032000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
29854000 usd
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
32456000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
103703000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
90600000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
379000 usd
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
370000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1137000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1109000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
61410000 usd
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
59276000 usd
us-gaap Costs And Expenses
CostsAndExpenses
190200000 usd
us-gaap Costs And Expenses
CostsAndExpenses
167134000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3908000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
10819000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-300000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
33529000 usd
CY2022Q3 us-gaap Other Income
OtherIncome
1553000 usd
CY2021Q3 us-gaap Other Income
OtherIncome
-97000 usd
us-gaap Other Income
OtherIncome
1987000 usd
us-gaap Other Income
OtherIncome
225000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5461000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
10722000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1687000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
33754000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2191000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2951000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2273000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7680000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
3270000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
7771000 usd
us-gaap Net Income Loss
NetIncomeLoss
-586000 usd
us-gaap Net Income Loss
NetIncomeLoss
26074000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.47
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.46
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56574503 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55668156 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56397805 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55467528 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56969033 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57040736 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56397805 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56818295 shares
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
3270000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
7771000 usd
us-gaap Net Income Loss
NetIncomeLoss
-586000 usd
us-gaap Net Income Loss
NetIncomeLoss
26074000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-37000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-17000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-83000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-48000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-24000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
33000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-1594000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-102000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-7000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
8000 usd
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-367000 usd
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-22000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-54000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
8000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1310000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-128000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3216000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7779000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1896000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
25946000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
504928000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4778000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6430000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1153000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
502123000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
125000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3830000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
2574000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-103000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
508549000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3888000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
3270000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-54000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
515657000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
453266000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1849000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3909000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
8650000 usd
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-47000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
467627000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
289000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3740000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
9653000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-89000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
481220000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
371000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3951000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
7771000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
8000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
493321000 usd
us-gaap Net Income Loss
NetIncomeLoss
-586000 usd
us-gaap Net Income Loss
NetIncomeLoss
26074000 usd
us-gaap Depreciation
Depreciation
933000 usd
us-gaap Depreciation
Depreciation
1026000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
12496000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
11600000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1160000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-1451000 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
12000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1137000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1109000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
713000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
5432000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1612000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1222000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2982000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11484000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9583000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2932000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3349000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2156000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
15070000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
860000 usd
vnda Increase Decrease Product Revenue Allowances
IncreaseDecreaseProductRevenueAllowances
2303000 usd
vnda Increase Decrease Product Revenue Allowances
IncreaseDecreaseProductRevenueAllowances
5417000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
22568000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
37607000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
416000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
418000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
344949000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
315187000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
319862000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
264907000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25503000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-50698000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
129000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2509000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
129000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2509000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2724000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10572000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52590000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61613000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49866000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51041000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management’s evaluation could change. Actual results could differ from those estimates.</span></div>
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49397000 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50522000 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
469000 usd
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
519000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49866000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51041000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
65318000 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
70095000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
189900000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
200663000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent
407255000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
453000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2314000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
405394000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent
381009000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
114000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
381000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
380742000 usd
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
405394000 usd
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
380742000 usd
CY2022Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
13000 usd
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
30000 usd
CY2022Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1577000 usd
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
995000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
1590000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
1025000 usd
CY2022Q3 vnda Inventory Raw Materials Net Of Reserves Non Current
InventoryRawMaterialsNetOfReservesNonCurrent
1332000 usd
CY2021Q4 vnda Inventory Raw Materials Net Of Reserves Non Current
InventoryRawMaterialsNetOfReservesNonCurrent
2143000 usd
CY2022Q3 vnda Inventory Work In Process Net Of Reserves Non Current
InventoryWorkInProcessNetOfReservesNonCurrent
7170000 usd
CY2021Q4 vnda Inventory Work In Process Net Of Reserves Non Current
InventoryWorkInProcessNetOfReservesNonCurrent
3934000 usd
CY2022Q3 vnda Inventory Finished Goods Net Of Reserves Non Current
InventoryFinishedGoodsNetOfReservesNonCurrent
965000 usd
CY2021Q4 vnda Inventory Finished Goods Net Of Reserves Non Current
InventoryFinishedGoodsNetOfReservesNonCurrent
1150000 usd
CY2022Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
9467000 usd
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
7227000 usd
CY2022Q3 vnda Inventory
Inventory
11057000 usd
CY2021Q4 vnda Inventory
Inventory
8252000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000 usd
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000 usd
CY2022Q3 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
14914000 usd
CY2021Q4 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
10082000 usd
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
8225000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
8732000 usd
CY2022Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5585000 usd
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5873000 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5769000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6515000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2199000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2311000 usd
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
13433000 usd
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
925000 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
50125000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
34438000 usd
vnda Agreements For Clinical And Marketing Services Termination Notice Period
AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod
P90D
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-51000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
32000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1434000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-207000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1485000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-175000 usd
vnda Share Based Compensation Option Awards Contractual Term
ShareBasedCompensationOptionAwardsContractualTerm
P10Y
vnda Share Based Compensation Arrangementby Share Based Payment Annual Award Vesting Period Employeesand New Directors
ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors
P4Y
vnda Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards
0.25
vnda Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards
0.75
vnda Sharebased Compensation Arrangementby Share Based Payment Award Options Vesting Period Number Of Equal Monthly Installments
SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments
36 installment
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.18
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.91
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2500000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M23D
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3888000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3951000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12496000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11600000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7700000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0203
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0075
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2200000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000000 usd
CY2022Q3 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
400000 usd
CY2021Q3 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
100000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2300000 usd
us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
1800000 usd
us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
200000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
3270000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
7771000 usd
us-gaap Net Income Loss
NetIncomeLoss
-586000 usd
us-gaap Net Income Loss
NetIncomeLoss
26074000 usd
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56574503 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55668156 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56397805 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55467528 shares
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
394530 shares
CY2021Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1372580 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1350767 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56969033 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57040736 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56397805 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56818295 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.47
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.46
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5238283 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2233806 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5199487 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2194547 shares

Files In Submission

Name View Source Status
vnda-20220930_cal.xml Edgar Link unprocessable
0001628280-22-027951-index-headers.html Edgar Link pending
0001628280-22-027951-index.html Edgar Link pending
0001628280-22-027951.txt Edgar Link pending
0001628280-22-027951-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vnda-20220930.htm Edgar Link pending
vnda-20220930.xsd Edgar Link pending
vndaex311930202210q.htm Edgar Link pending
vndaex312930202210q.htm Edgar Link pending
vndaex321930202210q.htm Edgar Link pending
vnda-20220930_def.xml Edgar Link unprocessable
vnda-20220930_lab.xml Edgar Link unprocessable
vnda-20220930_pre.xml Edgar Link unprocessable
vnda-20220930_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable